# LUMMICAR STUDY 2 (NCT03915184)

> Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03915184
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CARsgen Therapeutics Co., Ltd.
- Conditions: Multiple Myeloma
- Interventions: zevor-cel
- Enrollment: 105
- Primary outcome: Incidence of Treatment Related adverse events (AEs)
- Primary outcome: Identification of Maximum Tolerated Dose (MTD)
- Primary outcome: Objective response rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=lummicar-study-2-nct03915184